Siemens Healthineers expands radiotherapy beyond cancer, targets osteoarthritis pain

The radiotherapy systems include TrueBeam, TrueBeam STx, VitalBeam, and Edge

Japan okays new long-acting eye drug

It promises fewer injections for vision loss patients

Bayer wins world-first nod in Japan for low-dose MRI contrast agent

Call it a major breakthrough for diagnostic imaging

Bristol Myers Squibb unveils new Camzyos data, expands case for landmark heart drug

The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials

Zydus launches affordable Semaglutide in India after patent expiry

Targets diabetes & obesity crisis as India grapples with soaring metabolic disorders

AptarGroup nasal spray tech joins ENA respiratory’s Phase II trial of INNA?051

The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention

NATCO launches Semaglutide generic injection multi dose vials in India at affordable price of Rs. 1,290

Dr. Reddy’s Laboratories launches India’s first DCGI-approved Semaglutide injection ‘Obeda’ for type 2 diabetes

The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India

Bristol Myers Squibb scores major win with new Opdivo nods for Hodgkin Lymphoma in US, EU

These approvals represent a defining moment for people living with classical Hodgkin Lymphoma

Shionogi launches global Phase 2 trial for late-onset Pompe disease treatment

Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy